Target Name: MICU2
NCBI ID: G221154
Review Report on MICU2 Target / Biomarker Content of Review Report on MICU2 Target / Biomarker
MICU2
Other Name(s): 1110008L20Rik | EF-hand domain family, member A1 | Mitochondrial calcium uptake 2 | EFHA1 | EF hand domain family A1 | EF hand domain family, member A1 | mitochondrial calcium uptake 2 | Smhs2 homolog | Calcium uptake protein 2, mitochondrial | MICU2_HUMAN | EF-hand domain-containing family member A1

MICU2: A Potential Drug Target and Biomarker

MICU2 (1110008L20Rik), a gene located on chromosome 6, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and mental health conditions. Its unique genetic variation has led to the development of various phenotypes, making it an interesting study object.

MICU2 is a gene that encodes a protein known as MICU2, which is a key regulator of microRNA (miRNA) levels in the body. MiRNA is a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation by binding to specific target genes and regulating their translation into proteins.

The MICU2 gene has been associated with various diseases, including cancer, neurodegenerative disorders, and mental health conditions. For example, studies have shown that MICU2 is downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting MICU2 may be an effective way to treat these cancers.

In addition to its association with cancer, MICU2 has also been linked to a number of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and their dysfunction, leading to a range of symptoms.

The MICU2 protein has also been shown to be involved in the regulation of various mental health conditions, including depression, anxiety, and schizophrenia. Studies have shown that MICU2 is involved in the regulation ofmiRNA levels in these conditions, and that targeting MICU2 may be an effective way to treat these disorders.

The MICU2 gene has also been the subject of intense research due to its unique genetic variation. MICU2 has a variable exon splicing pattern, which means that different individuals may have different versions of the MICU2 gene. This has led to the development of various phenotypes of MICU2, each with its own unique expression level.

Studies have shown that MICU2 gene variants are associated with various cognitive and behavioral traits, including intelligence, personality, and mood. For example, research has shown that individuals with certain MICU2 gene variants may be at increased risk for developing depression and anxiety.

In addition, MICU2 has also been shown to play a role in the regulation of cellular processes that are important for brain development and function. For example, studies have shown that MICU2 is involved in the regulation of neurogenesis, the process by which new neurons are generated in the brain, and that this regulation may be important for the development and function of the brain.

Overall, MICU2 is a gene that has been studied extensively due to its potential as a drug target and biomarker. Its unique genetic variation and association with various diseases and conditions make it an interesting study object. Further research is needed to fully understand the role of MICU2 in these conditions and to develop effective treatments.

Protein Name: Mitochondrial Calcium Uptake 2

Functions: Key regulator of mitochondrial calcium uniporter (MCU) required to limit calcium uptake by MCU when cytoplasmic calcium is low (PubMed:24503055, PubMed:24560927, PubMed:26903221). MICU1 and MICU2 form a disulfide-linked heterodimer that stimulate and inhibit MCU activity, depending on the concentration of calcium (PubMed:24560927). MICU2 acts as a gatekeeper of MCU that senses calcium level via its EF-hand domains: prevents channel opening at resting calcium, avoiding energy dissipation and cell-death triggering (PubMed:24560927)

The "MICU2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MICU2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MICU3 | MID1 | MID1IP1 | MID1IP1-AS1 | MID2 | MIDEAS | MIDEAS-AS1 | MIDN | MIEF1 | MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2